Clinical Trial Update: A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing standard chemotherapy with or without BSI-201 (iniparib) for triple-negative metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• BSI-201 (iniparib)

Snippet

Sponsor: Sanofi | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED